

MIKA Pharma GmbH at A Glance

(As of June 27, 2008)

Core Business: Transdermal and transmucosal drug delivery

Founded: 1994

Headquarter: MIKA Pharma GmbH
An der Rheinschanze 1
67059 Ludwigshafen / Germany
www.mika-pharma.de
t.: +49 (0) 621 591 87-100
e-mail: info@mika-pharma.de


R&D facility: MIKA Pharma GmbH
Zentrum für Klinische Forschung und Entwicklung
Wielandstr. 28 A
32545 Bad Oeynhausen / Germany
t.: +49 (0) 5731 792 156

President/CEO: Bernd G. Seigfried,
President/CEO: Dr. rer. nat. Ralf K. H. Piotrowiak

Shareholders: Bernd G. Seigfried,
Dr. rer. nat. Ralf K. H. Piotrowiak
High Tech Private Equity GmbH

Business model: Approved drugs suitable for reformulation are identified, taken through clinical development and product registration and licensed to partners; major licensing deals with top 10 intl. pharmaceutical companies were successfully completed (human as well as animal health sector)

Employees: 17



*MIKA-diclofenac-spraygel
for the treatment of local pain and inflammation and
approved in 24 countries and offering:*

EFFICACY

*20fold higher drug transportation rate as compared to market
leading gels
2fold higher drug concentration in the target tissue as
compared to oral diclofenac tablets*

SAFETY

*50fold lower plasma level as compared to oral diclofenac
tablets
excellent skin tolerability*

Key Products: MIKA™-diclofenac-spraygel (MK03)
(diclofenac transdermal system based on the nano/microemulsion spraygel technology)
transdermal spray for the treatment of local pain and inflammation
approved in 32 countries

MIKA™-ketoprofen-spraygel (MK22)
(ketoprofen transdermal system based on the nano/microemulsion spraygel technology)
transdermal spray for the treatment of local pain and inflammation
approved in 6 countries

MIKA™-heparin-spraygel (MK31)
(heparin transdermal system based on the liposome spray technology)
liposomal transdermal spray for the treatment of sport injuries
first approvals obtained in 1994

MIKA™-MK49-spraygel
(systemically acting rapid pain reliever (buccal/transmucosal spray) based on the MIKA-RAPOSAL technology)

MIKA™-tarenflurbil-spraygel (MK50)
(tarenflurbil dermal/transdermal system based on the nano/microemulsion spraygel technology)
dermal/transdermal spray for the treatment of skin and joint diseases via a new mechanism of action

MIKA™-MK51-spray and MIKA™-MK52-spray
(potent and moderately potent corticosteroid with reduced content of active transdermal system based on MIKA-SILEC technology)

Further products under development

Research & Development: The entire portfolio of MIKA Pharma GmbH contains products and advanced projects in various fields of indications, e.g. pain, rheumatic disorders, sport injuries, superficial thrombophlebitis, cough, fungal infections, various skin disorders (atopic dermatitis, psoriasis) in order to just mention a few.

Core technologies: **Local targeted drug delivery technologies**

MIKA™-liposome spray technology (liposomal spray) - patented
MIKA™-spraygel technology (aqueous nano/microemulsion spray) - patented
MIKA™-SILEC technology (non aqueous reversed micellae spray) – patented

Non invasive rapid systemic drug delivery

MIKA™-RAPOSAL technology (transmucosal spray for rapid systemic drug delivery) – patent in preparation